Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) PT at $22.50

Pediatrix Medical Group, Inc. (NYSE:MD) has been given a consensus recommendation of “Hold” by the six brokerages that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $22.50.

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Friday, March 27th. UBS Group increased their price target on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 price target on shares of Pediatrix Medical Group in a report on Monday, April 20th. Truist Financial increased their price target on Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a report on Monday, April 13th. Finally, Mizuho set a $24.00 price target on Pediatrix Medical Group in a report on Friday, May 8th.

Pediatrix Medical Group Trading Up 1.3%

MD stock opened at $23.82 on Wednesday. The company has a market cap of $1.96 billion, a price-to-earnings ratio of 11.56 and a beta of 0.69. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.45. The business has a fifty day simple moving average of $22.76 and a 200-day simple moving average of $21.70. Pediatrix Medical Group has a 52 week low of $11.84 and a 52 week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The business had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. During the same period in the prior year, the firm posted $0.33 EPS. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, equities research analysts expect that Pediatrix Medical Group will post 2.1 EPS for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Several large investors have recently modified their holdings of MD. Wasatch Advisors LP acquired a new stake in shares of Pediatrix Medical Group during the first quarter valued at about $43,861,000. Victory Capital Management Inc. grew its stake in shares of Pediatrix Medical Group by 30.7% during the third quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after acquiring an additional 968,553 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Pediatrix Medical Group by 38.9% during the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after acquiring an additional 751,109 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Pediatrix Medical Group during the fourth quarter valued at about $13,613,000. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Pediatrix Medical Group by 814.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company’s stock valued at $12,713,000 after acquiring an additional 529,367 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.